Sign Out
Abrocitinib (Cibinqo) was administered in clinical studies up to a single oral dose of 800 mg. There is no experience with overdose of Abrocitinib (Cibinqo). There is no specific antidote for overdose with Abrocitinib (Cibinqo). In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Treatment should be symptomatic and supportive.
Pharmacokinetic data up to and including a single oral dose of 800 mg in healthy adult volunteers indicate that more than 90% of the administered dose is expected to be eliminated within 48 hours.
